PIC
PACB icon

Portland Investment Counsel’s Pacific Biosciences PACB Stock Holding History

Portland Investment Counsel’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-11,925
Closed -$98K – 39
2022
Q4 		$98K Hold
11,925
– – 0.06% 38
2022
Q3 		$69K Hold
11,925
– – 0.04% 37
2022
Q2 		$53K Hold
11,925
– – 0.03% 35
2022
Q1 		$109K Buy
+11,925
New +$137K 0.06% 35

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Portland Investment Counsel's PACB Position: Q1 2023 in Review

Portland Investment Counsel sold out of Pacific Biosciences (PACB) in Q1 2023, closing a stake of 11,925 shares — an estimated $98K sold.

Portland Investment Counsel first reported a position in PACB in Q1 2022 and held it in 4 quarters. The position peaked at $109K in Q1 2022. 259 funds tracked by Wall St. Rank hold PACB as of Q1 2023.

  • Portland Investment Counsel reported no remaining Pacific Biosciences position as of Q1 2023 after selling out during the quarter.
  • Portland Investment Counsel sold 11,925 Pacific Biosciences shares in Q1 2023, an estimated $98K.
  • Portland Investment Counsel first reported a position in Pacific Biosciences in Q1 2022 and held it in 4 quarters.
  • Portland Investment Counsel's Pacific Biosciences position peaked at $109K in Q1 2022.
  • 259 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2023.

Based on Portland Investment Counsel's 13F filing for Q1 2023, filed 12 May 2023.